84,998 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Purchased by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 84,998 shares of the company's stock, valued at approximately $1,124,000. Polar Asset Management Partners Inc. owned approximately 0.10% of Syndax Pharmaceuticals as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in SNDX. Soleus Capital Management L.P. lifted its stake in shares of Syndax Pharmaceuticals by 128.4% in the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after buying an additional 1,401,016 shares during the last quarter. Octagon Capital Advisors LP acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth $11,951,000. Renaissance Technologies LLC acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth $9,002,000. Trexquant Investment LP lifted its stake in shares of Syndax Pharmaceuticals by 1,309.7% in the fourth quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock worth $6,230,000 after buying an additional 437,859 shares during the last quarter. Finally, Altium Capital Management LLC acquired a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth $4,891,000.

Wall Street Analyst Weigh In

SNDX has been the subject of several research analyst reports. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Guggenheim reiterated a "buy" rating and set a $32.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. Scotiabank upped their target price on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research note on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.91.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock traded down $0.05 during mid-day trading on Friday, reaching $10.57. The company's stock had a trading volume of 1,808,471 shares, compared to its average volume of 1,785,806. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $25.07. The company has a market cap of $909.52 million, a P/E ratio of -2.91 and a beta of 0.82. The firm's 50-day moving average is $11.49 and its two-hundred day moving average is $13.39.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. The company's revenue for the quarter was up 1900.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.85) earnings per share. Sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).